Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) grants 222,452 RSUs to 29 new employees, with vesting over four years, subject to continued service. The awards were approved by the Compensation Committee as inducements for employment.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service relationship with Revance through the applicable vesting dates.

The Compensation Committee of Revance’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327126183/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

New Street Investor Relations:

Laurence Watts, 619-916-7620

laurence@newstreetir.com

Media

Revance Therapeutics, Inc.:

Cathryn Castaldo, 615-245-7567

cathryn.castaldo@revance.com

Source: Revance Therapeutics, Inc.

FAQ

How many RSUs were granted by Revance Therapeutics, Inc. (RVNC) to new employees?

Revance Therapeutics, Inc. (RVNC) granted 222,452 RSUs to 29 new employees.

How long is the vesting period for the RSUs granted by Revance Therapeutics, Inc. (RVNC)?

The RSUs granted by Revance Therapeutics, Inc. (RVNC) vest over four years.

What is the vesting schedule for the RSUs granted by Revance Therapeutics, Inc. (RVNC)?

25% of the underlying shares of the RSUs granted by Revance Therapeutics, Inc. (RVNC) vest on each of the four anniversaries of the applicable vesting commencement date.

Who approved the awards of RSUs at Revance Therapeutics, Inc. (RVNC)?

The Compensation Committee of Revance’s Board of Directors approved the awards.

Why were the RSUs granted by Revance Therapeutics, Inc. (RVNC) considered inducements?

The RSUs were considered inducements for the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).